Jump Financial LLC Purchases New Shares in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Jump Financial LLC bought a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 104,342 shares of the company's stock, valued at approximately $394,000. Jump Financial LLC owned 0.15% of Amylyx Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in AMLX. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Amylyx Pharmaceuticals by 43.4% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,263,353 shares of the company's stock valued at $4,775,000 after buying an additional 382,608 shares during the period. Wellington Management Group LLP purchased a new stake in Amylyx Pharmaceuticals in the fourth quarter worth $793,000. Renaissance Technologies LLC grew its stake in Amylyx Pharmaceuticals by 70.9% in the fourth quarter. Renaissance Technologies LLC now owns 464,400 shares of the company's stock worth $1,755,000 after purchasing an additional 192,600 shares during the period. Kennondale Capital Management LLC purchased a new stake in Amylyx Pharmaceuticals in the fourth quarter worth $508,000. Finally, ExodusPoint Capital Management LP purchased a new stake in Amylyx Pharmaceuticals in the fourth quarter worth $402,000. 95.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Mizuho raised Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and upped their price target for the stock from $3.00 to $7.00 in a research note on Monday, April 7th. HC Wainwright reissued a "buy" rating and issued a $12.00 target price on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 5th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.00.

Insider Activity at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, Director Bernhardt G. Zeiher bought 10,000 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The stock was bought at an average cost of $3.70 per share, for a total transaction of $37,000.00. Following the completion of the transaction, the director now owns 10,000 shares of the company's stock, valued at $37,000. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Joshua B. Cohen sold 11,851 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $3.47, for a total transaction of $41,122.97. Following the sale, the chief executive officer now owns 3,201,247 shares of the company's stock, valued at $11,108,327.09. This trade represents a 0.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 64,509 shares of company stock worth $222,586. 11.70% of the stock is owned by company insiders.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ:AMLX traded down $0.11 during midday trading on Tuesday, reaching $4.90. 546,850 shares of the company's stock traded hands, compared to its average volume of 1,245,654. The company has a market cap of $434.15 million, a price-to-earnings ratio of -1.28 and a beta of -0.53. Amylyx Pharmaceuticals, Inc. has a one year low of $1.58 and a one year high of $7.27. The stock has a 50 day moving average of $3.73 and a 200 day moving average of $4.18.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.06). The firm had revenue of ($0.67) million during the quarter. Sell-side analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.